-
Natural News Roundup (week 10/2022)
10 March 2022
GMO Advisory Committee COIs; EU endorses integrative cancer care; Dairy consumption & multiple sclerosis; Ask 'Dr' Alexa!; Designer fat mimics animal fat; Risk and liability from wireless tech; Common painkillers dampen immune response
-
Feature: Inflammaging—when older age, the modern world and our immune systems conspire
22 February 2024
On the lead up to the opening of the International College of Integrative Medicine’s Inflammaging conference in New Orleans, Rob Verkerk PhD introduces the subject, and the role of nucleotides and peptides in dealing with this spiralling problem.
-
Does mould matter?
21 March 2024
We joined Colab Services on 9th March to find out why the answer is a resounding Yes!
-
Guest Article: White lung pneumonia in children indirectly results from large-scale vaccination against SARS-CoV-2
06 December 2023
Vaccinologist, Geert Vanden-Bossche PhD, considers the recent spike in reports of white lung syndrome in children and it's relationship to covid 'vaccines'
-
Pathfinder Members' Briefing and Q&A - April 2024
25 April 2024
Recording of April's Members' Briefing and Q&A
-
Pathfinder Members' Briefing and Q&A - April 2024
25 April 2024
Recording of April's Members' Briefing and Q&A
-
Feature: Recalibrate your health by looking through a clinical psychoneuroimmunology lens
14 March 2024
The topline and a smorgasboard of clinical pearls from the recent CPNI Congress in Antwerp, Belgium
-
When you try to publish counter-narrative science….
14 March 2024
How a well-oiled machine swung into action to ensure a review revealing copious quality and safety concerns with COVID-19 vaccines was retracted
News / ANH Covid Zone / Health / Campaigns
-
ANH News Beat (week 22/2023)
31 May 2023
Our weekly roundup of the latest natural and covid news in one place. Read the headlines or click on the links to find out more
-
Regulatory limbo: the case of NAC
13 April 2023
The more effective a natural product, the greater the risk if it sits in an uncertain, regulatory ‘no man’s land’